The increased share reserve is a routine governance matter enabling future equity compensation but does not signal an immediate catalyst. Monitor upcoming clinical data readouts for IMUX's pipeline as the primary driver of stock movement.
Price Chart
Executive Summary
Immunic, Inc. held its annual meeting on June 29, 2026, where shareholders elected three Class III directors, approved an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000 to a total of 8,644,887, and ratified Baker Tilly as independent auditor. The equity plan amendment provides additional shares for future employee incentives but represents potential dilution.
Key Facts
- Shareholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing authorized shares by 6,000,000 to 8,644,887 shares.
- Michael Bonney, Thorvald Nagel, and Richard Rudick were elected as Class III directors to serve until the 2029 annual meeting.
- Baker Tilly US, LLP was ratified as independent registered public accounting firm for fiscal year 2026.
- Vote on the plan amendment: 4,391,782 for, 1,361,843 against, 24,538 abstain, with 3,107,100 broker non-votes.
Financial Impact
Potential dilution from up to 6,000,000 additional shares authorized for equity awards; no immediate financial impact.
Risk Factors
- Potential dilution from future equity grants under the expanded plan.
- No material operational or financial updates in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193805-26-000882 |
| Document: e665616_8k-immunic.htm | 0001193805-26-000882 |
| Document: 0001193805-26-000882-index-headers.html | 0001193805-26-000882 |
| Document: 0001193805-26-000882-index.html | 0001193805-26-000882 |
| Document: 0001193805-26-000882.txt | 0001193805-26-000882 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $12.19 | awaiting T+60 | — | $7.28 (−40.28%) |
Aug 11, 2026 11w ago | 8-K | $15.48 | awaiting T+60 | — | $7.28 (−52.97%) |
Jul 14, 2026 15w ago | 8-K | $14.69 $7.63 | ▼ −48.06% | ▼ −51.44% | $7.28 (−50.44%) |
Jun 29, 2026 17w ago | 8-K | $15.37 $9.37 | ▼ −39.04% | ▼ −42.60% | $7.28 (−52.64%) |
May 19, 2026 22w ago | 3 | $11.55 $16.06 | ▲ +39.05% | ▲ +34.04% | $7.28 (−36.97%) |
May 19, 2026 23w ago | 8-K | $11.60 $16.58 | ▲ +42.93% | ▲ +36.64% | $7.28 (−37.24%) |
Apr 30, 2026 25w ago | S-3/A | $9.65 $13.34 | ▼ −38.24% | ▼ −35.17% | $7.28 (+24.56%) |
Apr 23, 2026 26w ago | 8-K | $9.18 $15.00 | ▲ +63.40% | ▲ +58.38% | $7.28 (−20.70%) |
Apr 14, 2026 27w ago | 8-K | $11.10 $14.77 | ▲ +33.06% | ▲ +24.93% | $7.28 (−34.41%) |
Apr 10, 2026 28w ago | 8-K | $12.20 $14.77 | ▲ +21.07% | ▲ +12.14% | $7.28 (−40.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers